U.S. patients with sickle cell disease now have a novel treatment option: the first-ever CRISPR-based therapy.for use in patients age 12 years and older. In addition to offering hope of relief for people with severe forms of the painful blood disorder, the treatment, called Casgevy, is the world’s first to genetically tweak cells using theAnother gene therapy for sickle cell disease, called Lyfgenia and developed by biotech company bluebird bio, based in Somerville, Mass., was also approved December 8. Getting a green light for the first CRISPR-based medicine is exciting, says David Altshuler, chief scientific officer at Boston-based Vertex Pharmaceuticals, which developed the drug in a joint venture with CRISPR Therapeutics, a company in Cambridge, Mass. But the fact that the drug fills an unmet need for underserved patients is “more compelling to me, personally, than the fact that it’s CRISPR.” , most of them Black or Latino, have sickle cell disease. It is caused by a genetic defect in hemoglobin, the oxygen-carrying protein in red blood cells
U.S. patients with sickle cell disease now have a novel treatment option: the first-ever CRISPR -based therapy.for use in patients age 12 years and older. In addition to offering hope of relief for people with severe forms of the painful blood disorder, the treatment, called Casgevy , is the world’s first to genetically tweak cells using theAnother gene therapy for sickle cell disease , called Lyfgenia and developed by biotech company bluebird bio, based in Somerville, Mass.
, was also approved December 8. Getting a green light for the first CRISPR-based medicine is exciting, says David Altshuler, chief scientific officer at Boston-based Vertex Pharmaceuticals, which developed the drug in a joint venture with CRISPR Therapeutics, a company in Cambridge, Mass. But the fact that the drug fills an unmet need for underserved patients is “more compelling to me, personally, than the fact that it’s CRISPR.” , most of them Black or Latino, have sickle cell disease. It is caused by a genetic defect in hemoglobin, the oxygen-carrying protein in red blood cell
CRISPR Sickle Cell Disease Treatment Gene Therapy Casgevy Lyfgenia
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Solar Power Helps Texas Grid Pass Arctic Freeze TestRecord amount of solar power helps Texas grid withstand arctic freeze and prevent mass outages.
Weiterlesen »
RIF Wallet Launches on Rootstock, Offering Bitcoin-First Crypto Wallet SolutionRIF Wallet, a free open-source framework for building bitcoin first crypto wallets, has launched on Rootstock, the EVM-compatible Bitcoin sidechain. The self-custody solution is ideal for businesses and developers who want to quickly and easily offer users a Bitcoin-first crypto wallet.
Weiterlesen »
A First Look at the $45 Million Penthouse at the St. Regis Residences MiamiA luxurious penthouse in Miami with a price tag of $45 million is showcased. The architecture and location of the property are highlighted, offering a taste of luxury in a quiet neighborhood near the ocean and beach.
Weiterlesen »
Villanova suffers first home loss to St. John's since 1993St. John's defeats Villanova at their on-campus arena for the first time in 13 consecutive losses since 1993.
Weiterlesen »
Harvard's first Black female president resigns amid controversyClaudine Gay, Harvard University's first Black female president, has resigned following backlash for her testimony on antisemitism and allegations of plagiarism.
Weiterlesen »